Literature DB >> 11777543

GROalpha/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation-a role in Alzheimer's disease?

MengQi Xia1, Bradley T Hyman.   

Abstract

Inflammation has been implicated in the pathogenesis of Alzheimer's disease (AD) and other neurodegenerative diseases. We have examined the potential role of some chemokine/chemokine receptors in this process. It is known that CXCR2 is a strongly expressed chemokine receptor on neurons and is strongly upregulated in AD in a subpopulation of neuritic plaques. Here, we show that one of the CXCR2 ligand GROalpha/KC can be a potent trigger for the ERK1/2 and PI-3 kinase pathways, as well as tau hyperphosphorylation in the mouse primary cortical neurons. GROalpha immunoreactivity can be detected in a subpopulation of neurons in normal and AD. Therefore, the CXCR2-ligand pair may have a potent pathophysiological role in neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11777543     DOI: 10.1016/s0165-5728(01)00463-5

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  27 in total

Review 1.  CXC chemokine receptors in the central nervous system: Role in cerebellar neuromodulation and development.

Authors:  Davide Ragozzino
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 2.  Chemokine receptors and neural function.

Authors:  Charlene Cho; Richard J Miller
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

Review 3.  Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.

Authors:  Yong-Jing Gao; Ru-Rong Ji
Journal:  Pharmacol Ther       Date:  2010-02-01       Impact factor: 12.310

4.  Control of chemokine gradients by the retinal pigment epithelium.

Authors:  Guangpu Shi; Arvydas Maminishkis; Tina Banzon; Stephen Jalickee; Rong Li; Jeffrey Hammer; Sheldon S Miller
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-04-30       Impact factor: 4.799

Review 5.  Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors.

Authors:  Chang Liu; Guohong Cui; Meiping Zhu; Xiangping Kang; Haidong Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

Review 6.  Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller?

Authors:  Mike Veenstra; Richard M Ransohoff
Journal:  J Neuroimmunol       Date:  2012-03-22       Impact factor: 3.478

7.  Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease.

Authors:  Chunyan Zhu; Bing Xu; Xiaohong Sun; Qiwen Zhu; Yi Sui
Journal:  Mol Neurobiol       Date:  2016-11-23       Impact factor: 5.590

Review 8.  Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks.

Authors:  Bridgette D Semple; Thomas Kossmann; Maria Cristina Morganti-Kossmann
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-11       Impact factor: 6.200

Review 9.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

10.  Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases.

Authors:  Todd E Golde; Victor M Miller
Journal:  Alzheimers Res Ther       Date:  2009-10-12       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.